What is Minopen 2%?
Minopen 2% is used to treat pimples and red bumps (non-nodular inflammatory lesions) that occur with moderate to severe acne vulgaris in patients 12 years of age and older.
Minopen 2% capsules are used to treat bacterial infections in many different parts of the body. It is also used to treat anthrax infection and other infections in patients who cannot receive penicillins.
Minopen 2% belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth. However, Minopen 2% will not work for colds, flu, or other virus infections.
Minopen 2% is available only with your doctor's prescription.
Minopen 2% indications
Minopen 2%® Pellet-Filled Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms:
Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae.
Respiratory tract infections caused by Mycoplasma pneumoniae.
Lymphogranuloma venereum caused by Chlamydia trachomatis.
Psittacosis (Ornithosis) due to Chlamydia psittaci.
Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence.
Inclusion conjunctivitis caused by Chlamydia trachomatis.
Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis.
Relapsing fever due to Borrelia recurrentis.
Chancroid caused by Haemophilus ducreyi.
Plague due to Yersinia pestis.
Tularemia due to Francisella tularensis.
Cholera caused by Vibrio cholerae.
Campylobacter fetus infections caused by Campylobacter fetus.
Brucellosis due to Brucella species (in conjunction with streptomycin).
Bartonellosis due to Bartonella bacilliformis.
Granuloma inguinale caused by Calymmatobacterium granulomatis.
Minopen 2% is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Escherichia coli.
Enterobacter aerogenes.
Shigella species.
Acinetobacter species.
Respiratory tract infections caused by Haemophilus influenzae.
Respiratory tract and urinary tract infections caused by Klebsiella species.
Minopen 2%® Pellet-Filled Capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
Upper respiratory tract infections caused by Streptococcus pneumoniae.
Skin and skin structure infections caused by Staphylococcus aureus. (Note: Minopen 2% is not the drug of choice in the treatment of any type of staphylococcal infection.)
When penicillin is contraindicated, Minopen 2% is an alternative drug in the treatment of the following infections:
Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections.
Infections in women caused by Neisseria gonorrhoeae.
Syphilis caused by Treponema pallidum subspecies pallidum.
Yaws caused by Treponema pallidum subspecies pertenue.
Listeriosis due to Listeria monocytogenes.
Anthrax due to Bacillus anthracis.
Vincent’s infection caused by Fusobacterium fusiforme.
Actinomycosis caused by Actinomyces israelii.
Infections caused by Clostridium species.
In acute intestinal amebiasis, Minopen 2% may be a useful adjunct to amebicides.
In severe acne, Minopen 2% may be useful adjunctive therapy.
Oral Minopen 2% is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of Minopen 2% in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of Minopen 2% be reserved for situations in which the risk of meningococcal meningitis is high.
Oral Minopen 2% is not indicated for the treatment of meningococcal infection.
Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral Minopen 2% hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Minopen 2%® (Minopen 2% hydrochloride) Pellet-Filled Capsules and other antibacterial drugs, Minopen 2%® (Minopen 2% hydrochloride) Pellet-Filled Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Minopen 2%?
Use Minopen 2% extended-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Minopen 2% extended-release tablets. Talk to your pharmacist if you have questions about this information.
- Take Minopen 2% extended-release tablets by mouth with or without food. Taking Minopen 2% extended-release tablets with food or milk may decrease stomach upset. However, certain foods and milk may bind with Minopen 2% extended-release tablets, preventing its full absorption. Discuss any questions or concerns with your doctor.
- Swallow Minopen 2% extended-release tablets whole. Do not break, crush, or chew before swallowing.
- Take Minopen 2% extended-release tablets with a full glass of water (8 oz [240 mL]). Do not lie down for 30 minutes after taking Minopen 2% extended-release tablets.
- Do not take medicines that have aluminum, magnesium, calcium, or zinc (eg, multivitamins, antacids, quinapril), bismuth, or urinary alkalinizers (eg, sodium bicarbonate) in them within 2 hours before or after you take Minopen 2% extended-release tablets.
- Do not take medicines that have iron (eg, ferrous sulfate) in them within 3 hours before or 2 hours after taking Minopen 2% extended-release tablets. If you need to take iron, check with your doctor about the right type of iron to take along with Minopen 2% extended-release tablets.
- Minopen 2% extended-release tablets works best if it is taken at the same time each day.
- Do not miss any doses. If you miss a dose of Minopen 2% extended-release tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Minopen 2% extended-release tablets.
Uses of Minopen 2% in details
Use: Labeled Indications
Acute intestinal amebiasis: Adjunctive therapy to amebicides in the treatment of acute intestinal amebiasis
Acne:
Oral (immediate release) and IV:
Adjunctive therapy for the treatment of severe acne
Oral (extended-release):
Treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and older
Actinomycosis: Treatment of actinomycosis caused by Actinomyces israelii when penicillin is contraindicated
Anthrax: Treatment of anthrax caused by Bacillus anthracis when penicillin is contraindicated
Asymptomatic carriers of Neisseria meningitidis: Oral (immediate-release):
To eliminate the meningococci from the nasopharynx of asymptomatic carriers of N. meningitidis
Campylobacter: Treatment of infections caused by Campylobacter fetus
Cholera: Treatment of cholera caused by Vibrio cholerae
Clostridium: Treatment of infections caused by Clostridium spp when penicillin is contraindicated
Gram-negative infections: Treatment of infections caused by Acinetobacter spp, Escherichia coli, Enterobacter aerogenes, Shigella spp
Listeriosis: Treatment of listeriosis due to Listeria monocytogenes when penicillin is contraindicated
Meningitis: Treatment of meningitis due to Neisseria meningitidis when penicillin is contraindicated
Ophthalmic infections:
Treatment of inclusion conjunctivitis or trachoma caused by Chlamydia trachomatis
Relapsing fever: Treatment of relapsing fever caused by Borrelia recurrentis
Respiratory tract infections: Treatment of respiratory tract infections caused by Haemophilus influenzae, Klebsiella spp, or Mycoplasma pneumonia. For the treatment of upper respiratory tract infections caused by Streptococcus pneumoniae.
Rickettsial infections: Treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae
Sexually transmitted infections: Treatment of lymphogranuloma venereum caused by C. trachomatis; nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or C. trachomatis; donovanosis (granuloma inguinale) caused by Klebsiella granulomatis; syphilis caused by Treponema pallidum subspecies pallidum, when penicillin is contraindicated
Skin and skin structure infections: Treatment of skin and skin structure infections caused by Staphylococcus aureus (not considered a first-line agent for any staphylococcal infection)
Urinary tract infections: Treatment of urinary tract infections caused by Klebsiella species
Vincent infection: Treatment of Vincent infection caused by Fusobacterium fusiforme when penicillin is contraindicated
Yaws: Treatment of yaws caused by T. pallidum subspecies pertenue when penicillin is contraindicated
Zoonotic infections: Treatment of psittacosis (ornithosis) due to Chlamydia psittaci; plague due to Yersinia pestis; tularemia due to Francisella tularensis; brucellosis due to Brucella spp (in conjunction with streptomycin); bartonellosis due to Bartonella bacilliformis
Off Label Uses
Cellulitis (purulent) due to community-acquired MRSA
Based on the Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children, Minopen 2% is effective and recommended in the outpatient management of purulent cellulitis due to community-acquired methicillin-resistant S. aureus (MRSA).
Leprosy
Based on the National Hansen's Disease Program (NHDP) treatment recommendations, Minopen 2%, in combination with other agents, is an effective and recommended alternative agent for treatment of lepromatous (multibacillary) and tuberculoid (paucibacillary) leprosy.
Nocardiosis
Data from a limited number of patients studied suggest that Minopen 2%, with or without other concomitant antimicrobials, may be beneficial for the treatment of nocardiosis
Prosthetic Joint Infection
Based on the Infectious Diseases Society of America (IDSA) Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline, Minopen 2% (based on in vitro susceptibility) given for indefinite chronic oral antimicrobial suppression of prosthetic joint infections is an effective and recommended treatment option. Minopen 2% is one of the preferred agents for Staphylococci (oxacillin-resistant) infections and is an alternative treatment for infections caused by Cutibacterium spp.
Rheumatoid arthritis
Data from older controlled studies and a meta-analysis have demonstrated a beneficial effect on laboratory parameters and modest clinical benefit in patients with rheumatoid arthritis (RA). Some data suggest that Minopen 2% may be effective in patients with recent-onset disease to reduce the total steroid dose needed.
The American College of Rheumatology (ACR) updated guideline for the treatment of RA did not include Minopen 2% due to its infrequent use in RA and lack of new data since prior publication.
Minopen 2% description
Minopen 2% hydrochloride is a yellow, crystalline powder; sparingly soluble or soluble in water, slightly soluble in alcohol, practically insoluble in chloroform and in ether, dissolves in solutions of alkali hydroxides and carbonates.
Minopen 2% hydrochloride is 4-7, bis (dimethylamino)-1, 4, 4a, 5, 5a, 6, 11, 12a-octahydro-3,10,12, 12a-tetrahydroxy- 1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.
It has a molecular formula of C23H27N3O7 HCl. Molecular weight is 493.94.
Minopen 2% dosage
Minopen 2% Dosage
Generic name: Minopen 2% hydrochloride 45mg
Dosage form: tablet, film coated, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
The recommended dosage of Minopen 2%® is approximately 1 mg/kg daily for 12 weeks. Higher doses have not shown to be of additional benefit in the treatment of inflammatory lesions of acne, and may be associated with more acute vestibular side effects.
The following table shows tablet strength and body weight to achieve approximately 1 mg/kg.
Patient's Weight (lbs.) | Patient's Weight (kg) | Tablet Strength (mg) | Actual mg/kg Dose |
---|---|---|---|
99 – 120 | 45 – 54 | 45 | 1 – 0.83 |
121 – 170 | 55 – 77 | 65 | 1.18 – 0.84 |
171 – 225 | 78 – 102 | 90 | 1.15 – 0.88 |
226 – 276 | 103 – 125 | 115 | 1.12 – 0.92 |
277 – 300 | 126 – 136 | 135 | 1.07 – 0.99 |
Minopen 2%® Tablets may be taken with or without food. Ingestion of food along with Minopen 2%® may help reduce the risk of esophageal irritation and ulceration.
In patients with renal impairment, the total dosage should be decreased by either reducing the recommended individual doses and/or by extending the time intervals between doses.
More about Minopen 2% (Minopen 2%)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 80 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Minopen 2%
- Minopen 2% extended-release tablets
- Minopen 2% (Advanced Reading)
- Other brands: Minopen 2%, Dynacin, Myrac, Ximino, More (1) »
Professional resources
- Minopen 2% (FDA)
- Minopen 2% Hydrochloride eent (AHFS Monograph)
Related treatment guides
- Acne
- Rosacea
Minopen 2% interactions
See also:
What other drugs will affect Minopen 2%?
Anticoagulants
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Penicillin
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.
Methoxyflurane
The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
Antacids and Iron Preparations
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations.
Low Dose
Oral Contraceptives
In a multi-center study to evaluate the effect of Minopen 2% on low dose oral contraceptives, hormone levels over one menstrual cycle with and without Minopen 2% 1 mg/kg once-daily were measured. Based on the results of this trial, Minopen 2%-related changes in estradiol, progestinic hormone, FSH and LH plasma levels, of breakthrough bleeding, or of contraceptive failure, cannot be ruled out. To avoid contraceptive failure, female patients are advised to use a second form of contraceptive during treatment with Minopen 2%.
Drug/Laboratory Test Interactions
False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.
Minopen 2% side effects
See also:
What are the possible side effects of Minopen 2%?
Applies to Minopen 2%: oral capsule, oral capsule extended release, oral suspension, oral tablet, oral tablet extended release
Other dosage forms:
- intravenous powder for solution
As well as its needed effects, Minopen 2% (the active ingredient contained in Minopen 2%) may cause unwanted side effects that require medical attention.
Major Side Effects
If any of the following side effects occur while taking Minopen 2%, check with your doctor immediately:
Incidence not known:
- Black, tarry stools
- blistering, peeling, or loosening of the skin
- blood in the urine or stools
- blurred or double vision
- bulging soft spot on the head of an infant
- chest pain, possibly moving to the left arm, neck, or shoulder
- confusion
- diarrhea
- dizziness or lightheadedness
- eye pain
- fast heartbeat
- general feeling of discomfort or illness
- general tiredness and weakness
- hives, itching, or skin rash
- joint or muscle pain
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- loss of appetite
- nausea or vomiting
- red skin lesions, often with a purple center
- severe headache
- severe stomach pain
- sores, ulcers, or white spots on the lips or in the mouth
- troubled breathing
- unusual bleeding or bruising
- upper right abdominal or stomach pain
- yellow eyes and skin
Minor Side Effects
Some Minopen 2% side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Less common:
- Continuing ringing or buzzing or other unexplained noise in the ears
- difficulty with moving
- hearing loss
- hives or welts
- muscle stiffness
- redness of the skin
- sleepiness or unusual drowsiness
- Bloating
- discoloration of the tooth
- increased sensitivity of the skin to sunlight
- indigestion
- severe sunburn
Minopen 2% contraindications
See also:
What is the most important information I should know about Minopen 2%?
Do not use this medicine if you are pregnant. It could harm the unborn baby or cause permanent tooth discoloration later in life.
Minopen 2% can make birth control pills less effective. Ask your doctor about using a non hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while using Minopen 2%.
Minopen 2% passes into breast milk and may affect bone and tooth development in a nursing baby. Do not take this medication without telling your doctor if you are breast-feeding a baby.
Children should not take Minopen 2%. Minopen 2% can cause permanent yellowing or graying of the teeth in children younger than 8 years old.
Avoid exposure to sunlight or tanning beds. Minopen 2% can make you sunburn more easily. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.
Do not take iron supplements, multivitamins, calcium supplements, antacids, or laxatives within 2 hours before or after taking Minopen 2%. These products can make Minopen 2% less effective.
Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics.
Throw away any unused medicine after the expiration date on the label has passed. Using expired Minopen 2% can cause damage to your kidneys.
Active ingredient matches for Minopen 2%:
Minocycline in Japan.
List of Minopen 2% substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Minopen (Japan) | |
Minoplus (Germany) | |
Tablet, Film-Coated; Oral; Minocycline Hydrochloride (Rosen) | |
Tablets, Film-Coated; Oral; Minocycline Hydrochloride (Rosen) | |
Minoplus Forte | |
Tablet, Film-Coated; Oral; Minocycline Hydrochloride | |
Tablets, Film-Coated; Oral; Minocycline Hydrochloride | |
MINOPRIDE (India) | |
MINOPRIDE cap 50 mg x 10's (Innovative) | $ 2.35 |
MINOPRIDE cap 100 mg x 10's (Innovative) | $ 4.34 |
Minosil (Ireland) | |
Minosine (Taiwan) | |
Minosine 100 mg | |
Minostad (Austria) | |
Capsule; Oral; Minocycline Hydrochloride 50 mg (Stada) | |
Capsules; Oral; Minocycline Hydrochloride 50 mg (Stada) | |
Minostad 50 mg (Austria) | |
Minot (Peru) | |
Minotab (Argentina, Belgium, Luxembourg) | |
Minotab-100 (Luxembourg) | |
Minotabs (New Zealand, South Africa) | |
MINOTAG (India) | |
MINOTAG cap 50 mg x 10's (Ikon) | $ 2.35 |
MINOTAG cap 100 mg x 10's (Ikon) | $ 4.34 |
Minotas | |
Minotas 45mg Tablet ER (Intas Pharmaceuticals Ltd) | $ 0.23 |
Minotas 65mg Tablet ER (Intas Pharmaceuticals Ltd) | $ 0.32 |
Minotek (Netherlands) | |
Minotowa (Japan) | |
Minotrex (Portugal) | |
Minotrin 100 | |
Minotrin 50 | |
Minotyrol (Austria) | |
MINOVA | |
MINOVA 100 MG TABLET 1 strip / 4 tablets each (Cipla Ltd) | $ 0.58 |
Minova 100mg Tablet (Cipla Ltd) | $ 0.14 |
Minowil (Pakistan) | |
Minox 100 | |
Minox 50 (Ireland) | |
Minoz MR (Romania) | |
Minoz-OD (India) | |
Minoz-OD 100mg CAP / 10 (Ranbaxy (Croslands)) | $ 3.00 |
100 mg x 10's (Ranbaxy (Croslands)) | $ 3.00 |
MINOZ-OD cap 100 mg x 10's (Ranbaxy (Croslands)) | $ 3.60 |
Mirosin (Taiwan) | |
Mirosin 100 mg x 1's | |
Mylan-Minocycline (Canada) | |
Capsule; Oral; Minocycline Hydrochloride 100 mg | |
Capsule; Oral; Minocycline Hydrochloride 50 mg | |
Capsules; Oral; Minocycline Hydrochloride 100 mg | |
Capsules; Oral; Minocycline Hydrochloride 50 mg | |
Mylan-minocycline capsule 100 mg (Mylan Pharmaceuticals Ulc (Canada)) | |
Mylan-minocycline capsule 50 mg (Mylan Pharmaceuticals Ulc (Canada)) | |
See 623 substitutes for Minopen 2% |
References
- PubChem. "minocycline". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "minocycline". http://www.drugbank.ca/drugs/DB01017 (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Minopen 2% are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Minopen 2%. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology